{
    "name": "antihemophilic factor recombinant",
    "comment": "Rx",
    "other_names": [
        "Helixate FS",
        "Xyntha",
        "Kogenate FS",
        "NovoEight",
        "Recombinate",
        "Advate",
        "Eloctate",
        "Factor VIII (Recombinant)",
        "turoctocog alfa",
        "Obizur",
        "Nuwiq",
        "Adynovate",
        "Kovaltry",
        "Afstyla",
        "Jivi",
        "Esperoct",
        "Altuviiio",
        "efanesoctocog alfa"
    ],
    "classes": [
        "Coagulation Factors",
        "Hemostatics"
    ],
    "source": "https://reference.medscape.com/drug/helixate-fs-xyntha-antihemophilic-factor-recombinant-342152",
    "pregnancy": {
        "common": [
            "No data are available in pregnant women"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "No data are available regarding the presence in human milk, the effects on the breastfed infant, or the effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to mouse or hamster protein, or intolerance or allergic reaction to any components, including hamster proteins"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Use serial Factor VIII assays during treatment whenever possible to assure adequate Factor VIII levels are achieved and maintained",
                "Some products may contain Willebrand factor for stabilization; efficacy not established for treatment of Willebrand disease",
                "Clinical response to antihemophilic factor administration may vary; dosage must be individualized based on clinical response and coagulation studies, performed prior to treatment and regular intervals during treatment",
                "May form antibodies to mouse or hamster protein",
                " "
            ],
            "specific": [
                {
                    "type": "Monitoring laboratory tests",
                    "description": [
                        "Use individual factor VIII values for recovery and, if clinically indicated, other pharmacokinetic characteristics to guide dosing and administration",
                        "Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm that adequate factor VIII levels have been achieved and are maintained, when clinically indicated",
                        "Monitor for development of factor VIII inhibitors; perform assay to determine if factor VIII inhibitor is present when expected factor VIII activity plasma levels are not attained, or when bleeding is not controlled with expected dose",
                        "Use Bethesda Units (BU) to titer inhibitors"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Factor VIII inhibitor disorder",
            "percent": "31.7"
        },
        {
            "name": "Pyrexia",
            "percent": "5.9"
        },
        {
            "name": "Nausea",
            "percent": "1-4.4"
        },
        {
            "name": "Dizziness",
            "percent": "3.5"
        },
        {
            "name": "Headache",
            "percent": "3.5"
        },
        {
            "name": "Taste disorder",
            "percent": "2.7"
        },
        {
            "name": "Dyspnea",
            "percent": "1.8"
        },
        {
            "name": "Hypotension",
            "percent": "1"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Rash",
            "percent": "1"
        },
        {
            "name": "Swelling or redness at injection site",
            "percent": "1"
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Chills",
            "percent": null
        },
        {
            "name": "Vasodilation",
            "percent": null
        },
        {
            "name": "Hemorrhage",
            "percent": null
        },
        {
            "name": "Rhinitis",
            "percent": null
        },
        {
            "name": "Sore throat",
            "percent": null
        },
        {
            "name": "Stuffy nose",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Joint pain",
            "percent": null
        },
        {
            "name": "swelling",
            "percent": null
        },
        {
            "name": "Urticaria",
            "percent": null
        },
        {
            "name": "Reports of less than expected or lack of effect following antihemophilic factor VIII infusions which has resulted in unexpected bleeding into target joints and bleeding into new joints",
            "percent": null
        },
        {
            "name": "due to formation of activity",
            "percent": null
        },
        {
            "name": "neutralizing antibodies in patients previously receiving antihemophilic factor VIII",
            "percent": null
        }
    ]
}